Sulzer Medica shares drop on fears of surgery costs
This article was originally published in Clinica
Executive Summary
Sulzer Medica's shares continue to slide due to alarm over the consequences of the recall of its Inter-Op hip shell, which some believe may affect its spin-off from parent company Sulzer. The company had also informed the FDA of "potential problems" with a porous-coated tibial baseplate.